Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer

INTERVENTION: FOLFOX plus bevacizumab FOLFIRI plus bevacizumab CONDITION: metastatic colorectal cancer PRIMARY OUTCOME: Progression free survival SECONDARY OUTCOME: Overall survival, Time to treatment failure, Response rate, R0 resection rate, Toxicity, Quality of life INCLUSION CRITERIA: 1.Histologically documented metastatic measurable adenocarcinoma of the colorectum with no prior chemotherapies for metastatic disease. 2.Age: >20, <75. 3.ECOG PS of 0 or 1. 4.Adequate hematologic, renal, and hepatic function as defined by required baseline laboratory parameters. 5.Written informed consent.